CardioDynamics sold 76 BioZ system units during the first quarter of 2009, an increase of eight units compared with the same period last year.
Solid growth in the company's core business wasn't the only factor fueling first quarter optimism among CardioDynamics executives.
If cleared by the FDA,
CardioDynamics says it plans to utilize the BioZdTEL exclusively in its DiTEC (Diagnostic, Treatment and Education of Cardiac Disease) program that links kidney disease specialists with cardiologists.
Perry, CEO of
CardioDynamics stated, "We are very pleased with the record sales results and sales growth during the third quarter.
CardioDynamics (Nasdaq:CDIC), the ICG Company, is the innovator and global leader of breakthrough medical technology called Impedance Cardiography (ICG).
Perry, chief executive officer of
CardioDynamics, stated, "This marks our fifth sequential quarter of increased sales and is evidence that we are meeting our customers' needs for less expensive, less invasive hemodynamic monitoring solutions.
CardioDynamics' gross profit margin grew 8 percentage points to 71% while its net loss shrunk 62% to $732,000, or $0.10 per diluted share.
CardioDynamics International Corporation (Nasdaq: CDIC), manufacturer of BioZ(R) noninvasive digital cardiac output monitoring systems, San Diego, Calif., has announced that National Aeronautics and Space Administration (NASA) has placed an additional order for space research.
San Diego, CA-based
CardioDynamics, a manufacturer of impedance cardiography (ICG) technology, reported $7.2 million in net sales for the first quarter, a 10% increase from the first quarter of 2006.
(RAH223) MICHAEL PERRY -
CARDIODYNAMICS INTERNATIONAL CORPORATION (CDIC).
Perry, chief executive officer of
CardioDynamics, stated, "Receiving approval to market the BioZ System in Japan is pivotal for the Company and represents an opportunity similar to U.S.
(NAZ206) MICHAEL PERRY -
CARDIODYNAMICS INTERNATIONAL CORPORATION (CDIC).
